BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902]
URL: https://www.wjgnet.com/1007-9327/full/v14/i45/6902.htm
Number Citing Articles
1
Sanem Karadag Gecgel. Comparison of HBV-DNA Levels with Biochemical and Microbiological Parameters for Chronic Hepatitis Evaluation, Bursa, TurkeyJournal of Medical Microbiology and Infectious Diseases 2021; 9(1): 17 doi: 10.52547/JoMMID.9.1.17
2
Pietro Lampertico, Mala Maini, George Papatheodoridis. Optimal management of hepatitis B virus infection – EASL Special ConferenceJournal of Hepatology 2015; 63(5): 1238 doi: 10.1016/j.jhep.2015.06.026
3
Jiyun Fan, Ying Wang, Hui Xiong, Xiaokui Guo, Yung-chi Cheng. Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibilityJournal of General Virology 2014; 95(11): 2523 doi: 10.1099/vir.0.066886-0
4
Qingxian Cai, Fengjuan Chen, Xiaoqiong Shao, Xiaohong Zhang, Zhixin Zhao, Zhiliang Gao. Treatment of Pegylated Interferon-α2a in Chronic Hepatitis B Patients Demonstrating a Spontaneous Decline in HBV DNA after Acute ExacerbationAntiviral Therapy 2015; 20(2): 217 doi: 10.3851/IMP2832
5
Xianzheng Wang, Aihua Dong, Jingjing Xiao, Xingjun Zhou, Haili Mi, Hanqian Xu, Jiming Zhang, Bin Wang. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic miceCellular & Molecular Immunology 2016; 13(6): 850 doi: 10.1038/cmi.2015.64
6
Jianhua Hu, Yong Wang, Gongying Jiang, Jie Zheng, Tuxiang Chen, Zhiping Chen, Meifang Yang, Xuan Zhang, Hong Zhao, Lanjuan Li. Predictors of inflammatory activity in treatment-naive hepatitis B e-antigen-negative patients with chronic hepatitis B infectionJournal of International Medical Research 2020; 48(11) doi: 10.1177/0300060520969582
7
Spyros I. Siakavellas, George V. Papatheodoridis. Controversial Issues in Current Treatment of Chronic HBV InfectionCurrent Hepatology Reports 2015; 14(3): 164 doi: 10.1007/s11901-015-0268-4
8
Hui Zhang, Jianchun Xian, Yang Li, Li Xiao, Lu Wang, Muhammad Zia-Ul-Haq. Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-AnalysisEvidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/1889628
9
George V. Papatheodoridis. Hepatitis B virus treatment: Which patients can have treatment deferred?Clinical Liver Disease 2013; 2(1): 15 doi: 10.1002/cld.160
10
Wen-cong Li, Mao-rong Wang, Ling-bo Kong, Wei-guang Ren, Yu-guo Zhang, Yue-min Nan. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trialsBMC Infectious Diseases 2011; 11(1) doi: 10.1186/1471-2334-11-165
11
G. Papatheodoridis, V. Sypsa, M. Kantzanou, I. Nikolakopoulos, A. Hatzakis. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone surveyJournal of Viral Hepatitis 2015; 22(4): 409 doi: 10.1111/jvh.12314
12
Jiannis Vlachogiannakos, George V. Papatheodoridis. Optimal therapy of chronic hepatitis B: how do I treat HBeAg‐positive patients?Liver International 2015; 35(s1): 100 doi: 10.1111/liv.12719
13
EunYoung Ze, Eun Kyung Baek, Jong Jin Lee, Han Wook Chung, Dae Geon Ahn, Hwan Jun Cho, Jae Cheol Kwon, Hyung Joon Kim, HyunWoong Lee. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavirClinical and Molecular Hepatology 2014; 20(3): 267 doi: 10.3350/cmh.2014.20.3.267
14
Zhuo-Lun Song, Yu-Jun Cui, Wei-Ping Zheng, Da-Hong Teng, Hong Zheng. Application of nucleoside analogues to liver transplant recipients with hepatitis BWorld Journal of Gastroenterology 2015; 21(42): 12091-12100 doi: 10.3748/wjg.v21.i42.12091
15
Alexandra Alexopoulou, George V Papatheodoridis. Entecavir Treatment in HBV-Related Decompensated CirrhosisFuture Virology 2011; 6(11): 1275 doi: 10.2217/fvl.11.103
16
George V. Papatheodoridis, Emmanuel Tsochatzis, Svenja Hardtke, Heiner Wedemeyer. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic reviewLiver International 2014; 34(10): 1452 doi: 10.1111/liv.12565
17
Ting-Tsung Chang. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48Hepatology International 2009; 3(S1): 16 doi: 10.1007/s12072-009-9143-0
18
Munira Jahan, Shahina Tabassum, Mamun Al-Mahtab, Afzalun Nessa, Chowdhury Mohammad Shamim Kabir, Mohammad Kamal, Julio Cesar Aguilar. Hepatitis B Core Antigen in Hepatocytes of Chronic Hepatitis B: Comparison between Indirect Immunofluorescence and Immunoperoxidase MethodEuroasian Journal of Hepato-Gastroenterology 2015; 5(1): 7 doi: 10.5005/jp-journals-10018-1120
19
Jiannis Vlachogiannakos, George V. Papatheodoridis. HBV: Do I treat my immunotolerant patients?Liver International 2016; 36(S1): 93 doi: 10.1111/liv.12996
20
Melissa A. Cobleigh, Xin Wei, Michael D. Robek. A Vesicular Stomatitis Virus-Based Therapeutic Vaccine Generates a Functional CD8 T Cell Response to Hepatitis B Virus in Transgenic MiceJournal of Virology 2013; 87(5): 2969 doi: 10.1128/JVI.02111-12
21
Aslı Ormeci, Yucel Aydın, Abdullah Sumnu, Bulent Baran, Ozlem Mutluay Soyer, Binnur Pınarbasi, Suut Gokturk, Mine Gulluoglu, Derya Onel, Selim Badur, Filiz Akyuz, Cetin Karaca, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levelsInternational Journal of Infectious Diseases 2016; 52: 68 doi: 10.1016/j.ijid.2016.09.007
22
Zhengyan Wang, Ling Sun, Yuwan Wu, Qing Xia. Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology 2016; 40(2): 195 doi: 10.1016/j.clinre.2015.06.022
23
Valter Oberdan Borges de OLIVEIRA, Juliana Passos Rocha OLIVEIRA, Eloy Vianey Carvalho de FRANÇA, Hugo Leite de Farias BRITO, Tereza Virgínia NASCIMENTO, Alex FRANÇA. ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mLRevista do Instituto de Medicina Tropical de São Paulo 2016; 58(0) doi: 10.1590/S1678-9946201658065
24
Steven-Huy Han, Wuhua Jing, Edward Mena, Michael Li, Brett Pinsky, Hong Tang, Tony Hebden, Timothy Juday. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapyJournal of Medical Economics 2012; 15(6): 1159 doi: 10.3111/13696998.2012.710690